Novo, WuXi AppTec and Alexandria Venture Investments all invested in a Lepu Medical-led round that will support clinical trials for two cancer drug candidates.
Medical device producer Lepu Medical has led a $40m series C round for US-based oncology therapy developer Rgenix that included pharmaceutical firms Novo and WuXi AppTec.
Alexandria Venture Investments, a subsidiary of real estate investment trust Alexandria Real Estate Equities, also invested, as did Oceanpine Capital, Sofinnova Partners and Partnership Fund for New York City’s Innovate NY Fund. WuXi Apptec took part through its corporate venturing fund.
Rgenix is developing a small-molecule immunotherapy known as RGX-104 and is enrolling patients…
